Recent studies have focused on the convergence of GLP|GIP|glucagon receptor activator therapies and dopamine communication. While GLP agonists are commonly employed for managing type 2 diabetes mellitus, their unexpected impacts on reinforcement circuits, specifically governed by dopamine systems